Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)

ClinicalTrials.gov ID: NCT01764841

Public ClinicalTrials.gov record NCT01764841. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14 days over 48 weeks.

Study identification

NCT ID: NCT01764841
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bayer; Industry
Enrollment: 416 participants

Conditions and interventions

Conditions

Bronchiectasis

Interventions

Ciprofloxacin DPI (BAYQ3939) Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 2, 2013 (Actual)
Primary completion: Mar 9, 2016 (Actual)
Completion: Mar 9, 2016 (Actual)
Last update posted: Jan 24, 2018

2013 – 2016

United States locations

U.S. sites: 39
U.S. states: 20
U.S. cities: 37

Facility	City	State	ZIP	Site status
Not listed	Jasper	Alabama	35501	—
Not listed	Flagstaff	Arizona	86001	—
Not listed	Phoenix	Arizona	85006-2611	—
Not listed	Scottsdale	Arizona	85258	—
Not listed	Fort Smith	Arkansas	72901	—
Not listed	Los Angeles	California	90048	—
Not listed	Torrance	California	—	—
Not listed	Ventura	California	93003	—
Not listed	Farmington	Connecticut	06030	—
Not listed	Waterbury	Connecticut	06708-2513	—
Not listed	Washington D.C.	District of Columbia	20007-2197	—
Not listed	Celebration	Florida	34747	—
Not listed	Miami	Florida	33136	—
Not listed	Orlando	Florida	32803	—
Not listed	Weston	Florida	33331	—
Not listed	Winter Park	Florida	32789	—
Not listed	Lawrenceville	Georgia	30046	—
Not listed	Marietta	Georgia	30060	—
Not listed	Chicago	Illinois	60637	—
Not listed	Michigan City	Indiana	46360	—
Not listed	Hazard	Kentucky	41701	—
Not listed	Chesterfield	Missouri	63017	—
Not listed	Summit	New Jersey	07901	—
Not listed	New Hyde Park	New York	11042	—
Not listed	New York	New York	10016	—
Not listed	Portland	Oregon	97239-3011	—
Not listed	Philadelphia	Pennsylvania	19104	—
Not listed	Philadelphia	Pennsylvania	19140	—
Not listed	Charleston	South Carolina	29425	—
Not listed	Fort Worth	Texas	76104	—
Not listed	Houston	Texas	77030	—
Not listed	Houston	Texas	77043	—
Not listed	Kingwood	Texas	77339	—
Not listed	McKinney	Texas	75069	—
Not listed	Tyler	Texas	75708-3154	—
Not listed	Abingdon	Virginia	24210	—
Not listed	Richmond	Virginia	23225	—
Not listed	Spokane	Washington	99202-1334	—
Not listed	Tacoma	Washington	98405	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 112 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01764841, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 24, 2018 · Synced Oct 22, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01764841 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →